ARMYDA-4 RELOAD

12 Dec, 10

ARMYDA-4 RELOAD

Introduction

Clopidogrel reloading provides no overall benefit in patients on chronic clopidogrel therapy & undergoing PCI ; however beneficial in ACS subgroup: ARMYDA-4 RELOAD

Aim

To evaluate the efficacy and safety of clopidogrel reloading in patients undergoing percutaneous coronary intervention (PCI) & on chronic clopidogrel therapy

Patient Profile

Patients receiving chronic clopidogrel therapy (>10 days) & undergoing PCI (N = 503)

Study Groups

Reload group: 600 mg clopidogrel loading dose 4-8 h before PCI (n = 252)
Placebo group (n = 251)

Primary Endpoint

Mortality, myocardial infarction (MI), or target vessel revascularization at 30 days

Results

In the overall population, a non-significant reduction of 25% was observed in the reload group vs. placebo

Incidence of primary endpoint did not differ significantly in stable angina patients; whereas significant reduction of 66% was observed in patients with ACS

Safety

Bleeding risk similar in both groups (6% in both)

Conclusions

Clopidogrel reloading did not provide any overall benefit in patients on chronic clopidogrel therapy undergoing PCI
Significant benefit observed in subgroup of patients with ACS

Eur Heart J. 2010;31:1337-43